SCHEMBL5897079

SCHEMBL5897079

Nc1cc(NC(=O)c2ccnc(Cl)c2)ccc1Cl

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.54
POLB P06746 1/20 0.54
MAPK1 P28482 1/20 0.54
CA12 O43570 2/20 0.52
CA9 Q16790 2/20 0.52
NPC1 O15118 4/20 0.51
RAB9A P51151 4/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
KDM4E B2RXH2 1/20 0.51
MAPT P10636 1/20 0.51
PKM P14618 1/20 0.51
SLC6A3 Q01959 1/20 0.51
KCNH2 Q12809 1/20 0.51
TAAR1 Q96RJ0 1/20 0.51
KCNQ3 O43525 2/20 0.50
KCNQ2 O43526 2/20 0.50
KCNE1 P15382 2/20 0.50
KCNQ1 P51787 2/20 0.50
BCAT2 O15382 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5897217 0.84 LMNA (0.55) LMNAPOLBMAPK1CA12CA9
SCHEMBL16430829 0.81 PTGS1 (0.54) CA12CA9MAPTJAK2TYK2
SCHEMBL401850 0.81 KCNQ3 (0.64) LMNANPC1RAB9AMEN1KMT2A
SCHEMBL13546240 0.79 KCNQ3 (0.63) LMNAPOLBCA12CA9NPC1
SCHEMBL10890300 0.78 MEN1 (0.66) LMNAPOLBMAPK1CA12CA9
SCHEMBL4831562 0.78 NPC1 (0.73) NPC1RAB9AMEN1KMT2AKDM4E
SCHEMBL736261 0.78 LMNA (0.62) LMNAPOLBNPC1RAB9AKDM4E
SCHEMBL10830768 0.78 NPC1 (0.54) LMNAPOLBMAPK1NPC1RAB9A
SCHEMBL11574336 0.78 NPC1 (0.59) LMNAPOLBMAPK1NPC1RAB9A
SCHEMBL5897176 0.78 MAPK13 (0.62) LMNAMAPK1MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7060700-B2 Amide derivatives useful as inhibitors of the production of cytokines ASTRAZENECA AB (SE) 2006-06-13 US disclosed
US-20030105142-A1 Amide derivatives useful as inhibitors of the production of cytokines ASTRAZENECA AB 2003-06-05 US disclosed
US-6432949-B1 Amide derivatives useful as inhibitors of the production of cytokines ASTRAZENECA AB (SE) 2002-08-13 US disclosed
EP-1102750-A1 AMIDE DERIVATIVES USEFUL AS INHIBITORS OF THE PRODUCTION OF CYTOKINES AstraZeneca AB (SE) 2001-05-30 EP disclosed
WO-2000007991-A1 AMIDE DERIVATIVES USEFUL AS INHIBITORS OF THE PRODUCTION OF CYTOKINES ASTRAZENECA AB (SE) 2000-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105142-A1 Amide derivatives useful as inhibitors of the production of cytokines IL6, IL6ST, IL2 LMNA 2338/4885POLB 2146/4885MAPK1 1152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.